Executive Medical Director of Neurology, Global Medical Affairs

Zenas is a clinical-stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of transformative therapies for patients with autoimmune diseases. Our core business strategy combines our experienced leadership team with a disciplined product candidate acquisition approach to identify, acquire and develop product candidates globally that we believe can provide superior clinical benefits to patients living with autoimmune diseases. Zenas is advancing two late-stage, potential franchise molecules, obexelimab and orelabrutinib. Obexelimab, Zenas’ lead product candidate, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. We believe that obexelimab’s unique mechanism of action and self-administered, subcutaneous injection regimen may broadly and effectively address the pathogenic role of B cell lineage in chronic autoimmune disease. Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule Bruton’s Tyrosine Kinase (BTK) inhibitor with the potential to address compartmentalized inflammation and disease progression in Multiple Sclerosis (MS). Zenas’ earlier stage programs include ZB021, a clinical-stage, potentially best-in-class, oral, IL-17AA/AF inhibitor; ZB022, a preclinical, potentially best-in-class, oral, brain-penetrant, TYK2 inhibitor; and ZB014, a preclinical half-life extended anti-CD-19 and FcγRIIb monoclonal antibody. We are seeking top talent who share our commitment to patients and have a track record of success in acquiring, developing and commercializing products across the globe. Our colleagues have an opportunity to engage in a fast-paced learning environment and experience individual and organizational success as we work towards becoming a global immunology and autoimmune disease leader, while living our values of Transparency, Relationships, Urgency, Excellence and Innovation – TRUE Innovation ! Position Summary: Zenas BioPharma is seeking an experienced and visionary Executive Medical Director, Neurology to serve as the Global Medical Affairs medical lead for Multiple Sclerosis (MS). This individual will provide deep scientific, clinical, and strategic leadership across all aspects of Global Medical Affairs, including evidence generation, scientific communication, launch readiness, and external stakeholder engagement. The role will be central to shaping the global medical strategy for orelabrutinib and obexelimab in MS. The ideal candidate brings strong neurology expertise, clinical credibility in neurological disease, and a proven ability to translate complex science into impactful medical strategy and external engagement. Key Responsibilities: Medical Strategy & Leadership Serve as the global medical lead for neurology, defining and executing the overall medical strategy in alignment with development, regulatory, and commercial partners. Lead development of the Global Medical Affairs Plan, including scientific narrative, medical objectives, and evidence generation priorities. Ensure medical excellence across the lifecycle, from Phase 3 trial accrual, readout through launch and post-launch activities. Focuses on long-term strategic positioning, cross-portfolio integration, and global alignment across regions. Clinical & Scientific Expertise Act as the internal subject matter expert in neurology, providing scientific guidance to cross-functional teams. Lead interpretation of clinical data, secondary analyses, and emerging scientific insights to inform strategy, publications, and field training. Partner with Clinical Development on protocol design, endpoint refinement, PRO strategy, and data review and recruitment strategies for trials in neurology. External Engagement & Thought Leadership Build and maintain strong relationships with global KOLs,